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Abstract
Purpose To investigate the rhythm and predictability of the
need for retreatment with intravitreal injections of ranibizu-
mab for neovascular age-related macular degeneration
(nAMD).
Methods This prospective study enrolled 39 patients with
treatment-naïve nAMD. After three loading doses of intra-
vitreal ranibizumab, patients underwent an intensified
follow-up for 12 months (initially weekly, then with step-
wise increases to every 2 weeks and to monthly after each
injection). Patients were retreated on an as-needed basis if
any fluid or increased central retinal thickness (CRT)
(>50μm) was found on spectral domain optical coherence
tomography (OCT). Statistical analysis included patients
who received at least two retreatments (five injections).
Results A mean of 7.5 injections (range 0–12) were given
between months 3 and 15. The mean visual acuity increased
by 13.1 and 12.6 ETDRS letters at months 12 and 15 respec-
tively. Two or more injection–retreatment intervals were
found in 31 patients. The variability of their intra-individual
intervals up to 14 weeks was small (SD 0–2.13 weeks), re-
vealing a high regularity of the retreatment rhythm. The SD
was correlated with the mean interval duration (r00.89, p<
0.001). The first interval was a good predictor of the following
intervals (regression coefficient 00.81). One retreatment cri-
terion was stable in 97% of patients (cysts or subretinal fluid).
Conclusion The results of this study demonstrate a high
intra-individual predictability of retreatment need with rani-
bizumab injections for nAMD. These findings may be help-
ful for developing individualized treatment plans for
maintained suppression of disease activity with a minimum
of injections and visits.
Keywords Neovascular age-related macular degeneration .
Ranibizumab . Intravitreal injection . P.R.N. treatment
regimen . Predictability . Optical coherence tomography
Introduction
Age-related macular degeneration (AMD) is the leading
cause of severe and irreversible vision loss in people aged
50 years and older in developed countries [1, 2]. Recent
therapeutic gains have been made following the demonstra-
tion that the inhibition of vascular endothelial growth factor
A (VEGF-A) is an effective and safe therapy of neovascular
age-related macular degeneration (nAMD) when using
monthly injections of ranibizumab, a recombinant, human-
ized, monoclonal antibody fragment [3–5]. The MARINA
and ANCHOR trials used monthly treatments of ranibizu-
mab, while the PIER study employed quarterly injections
after three monthly loading doses [6, 7]. Although the
overall results of the PIER study demonstrated a smaller
benefit in mean visual acuity (VA), a subgroup of patients
did well on quarterly injections. Therefore, it appears that
some patients may not require monthly injections.
In an attempt to reduce the number of injections accord-
ing to individual need, two different approaches have been
developed. The pro re nata (p.r.n.) regimen, which involves
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monthly visits and retreatment according to predefined cri-
teria, has shown good functional outcomes [8, 9]. “Treat and
extend,” another flexible retreatment regimen (published
after initiation of the present study), showed a similar func-
tional outcome [10, 11]. This approach is based on the
progressive lengthening of treatment intervals until signs
of recurrence indicate a shortening of the treatment interval.
The underlying concept assumes a regular rhythmic pattern
in need of retreatment, although this concept remains un-
proven. The results of a recent study also suggests a regular
rhythmic pattern of recurrences, although the study’s retro-
spective design has inherent weaknesses [12].
The aim of the present study was to prospectively explore
the rhythm and predictability of the need for retreatment
with intravitreal injections of ranibizumab for nAMD. Such
predictability could allow for the future creation of an indi-
vidualised treatment plan with fewer visits and lower costs.
Methods
This prospective study was designed and carried out at a
single centre (University Eye Hospital Jules Gonin, Lau-
sanne, Switzerland). The study enrolled a consecutive series
of patients, aged 50 years or older, with newly diagnosed
treatment-naïve nAMD, with active subfoveal CNV as con-
firmed on fluorescein angiography by a retinal specialist. In
an attempt to recruit patients comparable to those in the
MARINA, ANCHOR, and PIER studies, we applied the
following inclusion criteria: baseline best-corrected visual
acuity (BCVA) between 0.5 and 0.06; an angiographically
identifiable CNV (both occult and classic) of 50 % or more
of the total retinal lesion; a total lesion size of no more than
12 disc diameters; and absence of any central atrophy or
fibrosis. In cases of bilateral nAMD, only one eye was
included in the study. Exclusion criteria were: pigment
epithelium tears; foveal atrophy, fibrosis or hemorrhage;
hemorrhage in more than 50 % of the lesion; confounding
retinopathy or vitreous pathology; and the inability to obtain
OCT images or fluorescein angiograms of sufficient quality.
Baseline examination included a complete ocular and
systemic history, BCVA measured at 4 m with standard
ETDRS charts, a complete ophthalmic examination with
slit-lamp biomicroscopy, intraocular tonometry, dilated fun-
doscopy, color fundus photographs, fluorescein and indoc-
yanine green angiography (FA and ICGA), fundus
autofluorescence, and spectral domain optical coherence
tomography (SD-OCT; Cirrus, Carl Zeiss Meditec, Inc.,
Oberkochen, Germany) with a cube 512 × 126.
The initial treatment consisted of three intravitreal injec-
tions of ranibizumab (0.5 mg) at monthly intervals. All
injections were performed by a retina specialist according
to the internationally standard technique.
From injection 3, the intervals between injection and
need for the next injection were measured. To detect signs
of exudative activity early and to increase the precision of
the study, follow-up visits were stepped up between month 3
and month 15: With the previous injection serving as a time
reference, the visits occurred on a weekly basis from the
earliest time point of possible retreatment (week 4, 5, 6, 7,
8 post injection), followed by visits every 2 weeks until
week 16 (post injection), and then monthly visits after each
injection, until retreatment criteria were met (explained be-
low). Then, the interval count was reset to 0 at the date of
retreatment, and visits were again performed at week 4,5,6,
etc as described above. Visit intervals were increased grad-
ually in order to maintain compliance, and with the assump-
tion that longer recurrence-free intervals would be
associated with slower progression from dry retina to clin-
ically detectable exudative recurrence, due to lower under-
lying disease activity.
The examinations at follow-up visits included BCVA, in-
traocular tonometry, fundoscopy, and SD-OCT with a
512 × 126 cube. If fixation was extrafoveal, the fovea was
manually centred into the cube measurement. Dilatation was
not necessarily performed, if the quality of SD-OCT was at
least 7/10, as indicated by the integrated software, and if
fundoscopy showed no hemorrhage. FA and fundus autofluor-
escence were repeated at month 3 and at the final visit, and
also in between, if judged necessary. Criteria for retreatment
were the presence of any intraretinal cysts or subretinal fluid
(SRF), or an increase of central retinal thickness (CRT) of at
least 50μm, as compared with the smallest previous measure-
ment. In an attempt to differentiate between exudative and
degenerative cysts, the cysts were accepted as retreatment
criterion only if they were associated with some exudation
on FA, or if they re-appeared on SD-OCT after transient
absence, or if they were associated with an increased CRT of
>50μm. In unclear cases, one investigator (IM), blinded to the
previous evolution, decided whether retreatment criteria were
met, based on the OCT scans and FA images. If retreatment
criteria were met, a single re-injection with intravitreal ranibi-
zumab was performed within 3 days after the visit, and the
interval count was reset to 0 at the date of injection. The
intervals between the previous injection and the visit that
revealed exudative signs on SD-OCTwere determined. These
intervals were defined as “retreatment intervals” because of
evidence indicating the need for retreatment, even though the
re-injection may have been given up to 3 days later. The
retreatment intervals were determined from injection 3
through month 15, including one additional interval (if ascer-
tainable) up to month 18. However, the last injection after
month 15 was not included in the count of injections given
during the 12 months of p.r.n. follow-up.
If a patient missed a visit but had a dry macula on the
next visit, the patient was allowed to continue in the study.
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However, if a patient missed a visit and had exudative signs
on the SD-OCT of the next visit, the corresponding interval
was excluded from the study.
Statistical analyses (software: Stata 11, StataCorp LP,
College Station, TX, USA) were performed by the Centre
of Clinical Epidemiology of the Institute of Social and
Preventive Medicine (Lausanne, Switzerland). Statistical
analysis of the intervals included all patients in whom we
observed and documented at least two intervals of retreat-
ment after the loading phase. The standard deviation (SD) of
the intra-individual intervals was used to describe the vari-
ability of the intervals. To test the relation between the
variability of intervals (SD) and the mean intra-individual
intervals, a correlation test was performed with Spearman’s
rho test (non-normal distribution). To test the predictive
capacity of the first interval with regards to the following
intervals, a multilevel model was used with patients as
random effect, and with measures nested into the patients,
in order to take into account the dependence of the measure-
ments of the same patient. A p-value <0.05 was considered
statistically significant.
The study was approved by the local ethics committee,
and it adhered to the tenets of the declaration of Helsinki.
All patients gave written informed consent.
Results
A total of 39 patients were included in the study. Their mean
age was 79.4 years (SD 7.2); 30 were female and nine male.
The study eye was the right eye in 23 patients and the left
eye in 16 patients. Predominantly classic CNV was found in
nine patients (including six purely classic), minimally clas-
sic CNV in one patient, occult CNV in 24 patients, and
retinal angiomatous proliferation (RAP) in five patients.
Some pigment epithelium detachment was observed in six
patients (four occult CNV, one minimally classic CNV, one
RAP), and 12 patients had lesions larger than 4 disc
diameters.
Patients received a mean of 7.5 injections during the
12 months of p.r.n. follow-up. The mean BCVA improved
by 6.4 ETDRS letters at month 3, and continued to improve
to a mean gain of 13.1 and 12.6 ETDRS letters at month 12
and month 15 respectively (Fig. 1). At month 12 and 15, no
patient had lost 3 lines or more of BCVA, 92 % had stable or
improved BCVA, and 36 % / 33 % of patients respectively
had BCVA improvement from baseline of more than three
lines ETDRS. Mean CRT rapidly diminished by 103 micro-
meters at month 3, and remained stable thereafter (Fig. 1).
There were 31 patients with at least two retreatment
intervals during the p.r.n. follow-up (including the last in-
terval measurement after month 15, if available), which
ranged between 4 and 14 weeks (Table 1). One patient had
a much higher mean intra-individual value (32 weeks). Our
statistical consultant reckoned that a single measurement in
a different range would not allow any conclusions regarding
this interval range, and recommended not including that
patient in the statistical analysis.
The results of mean intervals and SD are shown in Fig. 2.
SD ranged between 0 and 2.13 weeks in all patients, and
between 0 and 1.97 weeks in 95 % of the patients, with a
95 % confidence interval for the upper limit of 1.36–2.13. A
correlation analysis of the intra-individual interval means
and the associated SD values showed a strong and statisti-
cally significant correlation with Spearman’s rho00.89 (p<
0.0001); that is, the SD increased with the intra-individual
mean intervals.
The rhythm of 11 eyes (35 %) was highly regular, with an
SD of zero: ten of them showed signs of liquid on SD-OCT
as defined in the Methods section at each 4-week visit,
indicating a regular 4-weekly rhythm of need for retreat-
ment. One patient showed recurrences exclusively at
6 weeks after each injection. The remaining 20 patients
(65 %), with a mean interval between 4 and 14 weeks, had
some variation in their intervals with a relatively small SD,
between 0.3 and 2.13 weeks. In eight patients, the variability
was limited to the two most proximate interval durations
(weeks 4+5, or weeks 8+10, or weeks 12+14). Their SD
was between 0.36 and 0.49 for measurements with a preci-
sion of 1-week units (weeks 4+5), and ranged between 0.75
and 0.94 for the longer intervals, influenced by the 2-week
visit interval (weeks 8+10, weeks 12+14). Thus, a total of
19 patients (61 %) had either constant or two adjacent
interval durations.
The first measured interval after the three loading doses
was a good predictor of the following intervals. The regres-
sion coefficient of the multilevel model was 0.81 (95 %
confidence interval 0.67–0.95), which is significantly dis-
tanced from zero. The first interval was predictive of 70 %
of the variance of the following intervals. For each unit of
duration of the first interval, the following intervals are
equal to 0.81 times the first interval, added to a constant of
1.21 (statistical equation: probable future interval01.21+
0.81*first interval).
We analyzed factors that could potentially influence the
mean interval duration, including age, baseline VA, baseline
CRT, the angiographic lesion type, and the baseline lesion
size. None of these factors, however, showed any associa-
tion with the mean retreatment interval. Furthermore, no
particular characteristic was found for the patients with only
one or no recurrence.
The retreatment criteria involved SRF in 24 eyes, cysts
(re-appearing or associated with exudation of FA or associ-
ated with CRT increase >50 μm) in 24 eyes, and CRT
increases of at least 50 μm in 11 eyes. In the 32 eyes with
at least two intervals, accumulation of SRF was observed as
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a revenant retreatment criterion in all subsequent recurren-
ces in 17 eyes, and cysts in a further 14 eyes; therefore, one
of these two criteria remained stable in 31 (97 %) out of 32
eyes. One eye showed, alternatively, cysts or SRF. However,
a CRT increase of at least 50 μm was observed exclusively
in association with cysts or subretinal fluid, but never as an
isolated retreatment criterion.
Discussion
The present study prospectively explored the rhythm and
predictability of the need for retreatment with intravitreal
injections of ranibizumab for nAMD. The results showed a
relatively high consistency of the intra-individual intervals
over time (in the range of means of 4-14 weeks), as reflected
by very small standard deviations, particularly in association
with smaller individual means. Because the small standard
deviation indicates high stability over time, we may con-
clude that there is a relatively good predictability of the need
for retreatment. In fact, the first measured interval duration
was shown to have a good predictive value, explaining 70 %
of the variance of the following intervals. In most cases, the
interval corresponds with a true recurrence (21 patients out
of 31 had transiently dry macula, 68 %). Also, slightly
earlier regular retreatment may make it possible to keep
the macula mostly dry.
To the best of our knowledge, no previous prospective
study has measured the degree or regularity and predictabil-
ity of the intra-individual need for retreatment for patients
with nAMD treated with intravitreal ranibizumab. However,
a recent retrospective study has found at least two periodic
injection-recurrence intervals in 76 % of eyes with 2–6
recurrences [12]. Furthermore, a recently described p.r.n.
regimen, called “treat and extend”, was shown to result in
good functional results [10, 11, 13]. In this regimen, the
treatment interval was progressively increased by incre-
ments of 2 weeks, until the follow-up visit disclosed signs
of exudation, justifying a subsequent reduction to the previ-
ous interval. Thus, the “treat and extend” regimen was based
on the assumption of a relatively regular rhythm of the need
for retreatment. The results of our current study support that
underlying assumption.
A regular rhythm of recurrences is not surprising if we
assume that a continuous and stable production of VEGF by
the underlying nAMD (and a stable elimination rate) results
in a stable level of VEGF in the retina, and also assume
stable individual pharmacokinetics. These assumptions
could explain that the point of clinically relevant concentra-
tion of free VEGF is reached always after the same period of
time following the latest standard injected dose of anti-
VEGF. Furthermore, the intravitreal half-life of ranibizumab
has been measured to be approximately 3 days in rabbits and
monkeys [14, 15], and may be up to 9–10 days in humans
Fig. 1 Mean best-corrected vi-
sual acuity change (ETDRS
letters) and mean central retinal
thickness change (micrometers)
from baseline of all study eyes
treated with intravitreal ranibi-
zumab for neovascular age-
related macular degeneration
(error bars indicate standard
error of change)
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[16], which is sufficiently short to obviate any accumulation
of the drug due to repeated injections.
The intervals of a subset of patients showed an SD of 0
(n011, 35 %) — a perfectly regular rhythm and perfect
predictability of future need for treatment. Apart from one
patient with a regular 6-week interval, these were mostly
patients with persistent exudative signs at their week 4 visits
(n010, 32 %). These exudative signs may be unresponsive
to treatment or may be very early recurrences before week 4.
Studies like PrONTO [8] have established that a subgroup
of patients showed signs of active nAMD on each monthly
visit, requiring monthly anti-VEGF treatment. The number
of these patients was relatively high in our study, probably
reflecting both our choice of mild changes as being suffi-
ciently indicative of active disease, and the high sensitivity
of SD-OCT to detect these changes. However, cystic
changes on SD-OCT may be degenerative rather than exu-
dative. In an attempt to differentiate them and exclude
purely degenerative cysts, we required an association with
new appearance or CRT increase or exudation on FA for
acceptance as retreatment criterion.
A second subset of patients (n021, 68 %) showed a mean
individual retreatment interval of >4 weeks, i.e., transiently
dry macula on OCT and subsequent recurrence of exuda-
tion. The standard deviation of the mean intra-individual
intervals was small in this group, indicating moderate fluc-
tuation of the intervals over time. The observed correlation
with the mean intervals may be explained by three mecha-
nisms. First, it might be related to a certain imprecision in
the measurement of intervals — initially weekly visits (dur-
ing month 2 post injection) changed to biweekly visits
(during months 3 and 4 post injection) and finally to month-
ly visits after each injection. This would lead to higher
standard deviations associated with later recurrences, once
an interval differs. Second, longer intervals lead to smaller
numbers of intervals measured and therefore to larger SD.
Third, the underlying disease activity may not always be
exactly the same, and the pharmacokinetics may also be
subject to some changes over time. If this is the case, we
would expect a bigger impact of mild changes on the vari-
ability of intra-individual intervals in patients with relatively
low retinal concentrations of VEGF and later recurrences.
The drug elimination curve becomes flatter over time, and
relatively small fluctuations in VEGF production may lead
to significantly earlier or later time points at which free
VEGF is present and causes an exudative recurrence.
Nevertheless, the first measured interval after the initial
three loading doses showed a good predictability of the
following intervals, explaining 70 % of their variance. This
may allow quite reliable estimation of future need for
retreatment, based on only one early interval measurement.
The regression formula found for the relationship between
first interval and the following intervals (probable futureTa
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interval 0 1.21+0.81*first interval) describes that for longer
intervals the first interval tends to be longer than the fol-
lowing intervals. Since the first interval is the one that
follows three loading injections, it may be that loading has
a more profound effect on the new vessel formation and
exudation than a single injection for exudative recurrence
thereafter.
We tried to evaluate possible associations of baseline
characteristics with the mean interval duration. Although
no such association was found for age, baseline VA, base-
line CRT, the angiographic lesion type, or the baseline
lesion size, no firm conclusion can be drawn, because the
power of the study was insufficient to address this question.
The functional and structural results (BCVA and CRT)
were excellent in this study. We found a continuous im-
provement of the mean BCVA (+6.4 letters at month 3,
+13.1 letters at month 12), to a degree that the functional
results appear to be just as good as in the MARINA and
ANCHOR studies under monthly retreatment (+5.1 to +10.0
letters at month 3, +6.5 to +11.3 letters at month 12) [3–5].
Although p.r.n. regimens often have been associated with
secondary functional losses after the loading dose [17–19],
it has been shown that strict monthly visits and sensitive
retreatment criteria may achieve good and durable function-
al results [8, 20, 21]. Our mean of 7.5 injections during the
12 months p.r.n. follow-up is relatively high, reflecting early
retreatment due to sensitive recurrence criteria and increased
number of follow-up visits. This may have had a beneficial
effect on the functional results. However, the rationale
behind the intensified follow-up was consistent with the
study’s aim to determine retreatment intervals; we do not
make any recommendation as to follow-up frequency.
We acknowledge that the present study has some weak-
nesses. The number of patients was limited. No follow-up visit
was performed before week 4 after each injection, resulting in
the absence of information about complete or incomplete
absorption of liquid during these periods. However, because
re-injection was not permitted before the 4-weeks interval, we
chose to focus on the subsequent weeks in our protocol, in an
attempt to conserve the patients’ motivations for the more
important time period. For the same reason, we decided to
slowly decrease the visit frequency. A theoretical justification
for this decision may be explained by the pharmacokinetics of
ranibizumab, assuming that the parabolic curve of drug con-
centration leads to slower and milder exudative recurrences
the longer it takes for free VEGF to appear (lower VEGF
secretion). This, however, caused some statistical heterogene-
ity of the interval measurements, and influenced the standard
deviations (see explanation above). Furthermore, the transi-
tion from dry macular to exudative recurrence, as judged on
OCT by the presence of SRF or cysts, may not be sharply
demarcated. Therefore, subjective judgements are likely to
have played a role. We attempted to offset this risk by using
a masked reader (see Methods section). Finally, the study was
limited to 12 months of p.r.n. follow-up, resulting in a lack of
information about the predictability of longer intervals. The
natural time course of nAMD may influence the need for and
timing of treatment in the long term.
Fig. 2 Graphic presentation of
the individual mean values
(between 4 and 14 weeks) of
retreatment intervals of study
eyes with at least two measured
intervals (n031 eyes) with
exudative activity in age-related
macular degeneration after
treatment with intravitreal in-
jection of ranibizumab. The
mean values are shown as bar
with a dark dot at the end, and
positive standard deviation is
added as a T-Line
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The results of the present study do not yet allow us to
recommend new treatment regimens. However, the study
results provide important information that may contribute
to the future development of a secure treatment plan with a
minimum number of visits and injections — still allowing
the same good functional outcome, while reducing the
workload and cost: The presence of a regular rhythm and
good predictability of need for retreatment may allow an
individual treatment plan. However, the variability of the
intervals, although small, requires the ideal future regimen
to be dynamic, sensitive and combined with a feedback
system.
In summary, the present study demonstrates that patients
with nAMD, given three initial loading doses of intravitreal
ranibizumab, show relatively stable and predictable need for
retreatment — for those with intervals up to 14 weeks, and
during the first year of follow-up. The findings suggest that
measurements of the initial interval may play a role in
developing future treatment regimens with optimal timing
of injections and reduction of costs, while still allowing
excellent outcome. Further studies will be needed, however,
to apply these results in the clinical care of patients with
nAMD
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